ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

8:30AM-10:30AM: Abstract Number: 1169

Patient Preferences for Outcome Measures for a Pragmatic Knee Osteoarthritis (OA) Clinical Trial: Results of a Cross-Sectional Patient Survey That Included Racial/Ethnic Minorities

Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Abstract Number: 1418

Patient Reported Outcomes on Quality of Life in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

8:30AM-10:30AM: Abstract Number: 1122

Patient-perceived Solutions to the Treatment Barriers in Knee Osteoarthritis: A Qualitative Study from a Diverse Patient Group Including Racial/ethnic Minorities

Osteoarthritis – Clinical Poster III (1118–1134)

8:30AM-10:30AM: Abstract Number: 1289

Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms

SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

8:30AM-10:30AM: Abstract Number: 1163

Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence

Patient Outcomes, Preferences, & Attitudes Poster III: Patient Preferences (1153–1169)

8:30AM-10:30AM: Abstract Number: 1197

Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1213

Persisting Pain in Rheumatoid Arthritis – an Essential yet Underrated Challenge

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1064

Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Private Rheumatology Practice: Patient Outcomes

Health Services Research Poster II: Care Models and Innovation (1061–1082)

8:30AM-10:30AM: Abstract Number: 1106

Phenotypes and Genotypes of NLRP3-AID in Chinese Adult Patients

Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

8:30AM-10:30AM: Abstract Number: 1033

Physical Inactivity Among Adults with Specific Chronic Conditions, by Arthritis Status, 49 States and District of Columbia, Behavioral Risk Factor Surveillance System, 2019

Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

8:30AM-10:30AM: Abstract Number: 1233

Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1182

Pilot Health Literacy Curriculum Addressing Skills and Content Knowledge for Adult and Pediatric Rheumatology Fellows

Professional Education Poster (1170–1195)

8:30AM-10:30AM: Abstract Number: 1209

Plasma Calprotectin as a Biomarker of Active Synovitis in Rheumatoid Arthritis: A Clinical and Ultrasound Study in Patients Treated with Il6 and JAK Inhibitors

RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)

8:30AM-10:30AM: Abstract Number: 1247

Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis

RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)

8:30AM-10:30AM: Abstract Number: 1172

Podcast-Based Learning, a Valuable Tool for Learning Rheumatology

Professional Education Poster (1170–1195)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].